China's Shenzhen Hepalink takes 10% stake in ProMetic; signs research deal

China's Shenzhen Hepalink takes 10% stake in ProMetic; signs research deal
ProMetic Life Sciences Inc. (TSX:PLI) is moving to expand its presence in Asia through strategic agreements that will see China's Shenzhen Hepalink Pharmaceutical Co. Ltd. take a 10 per cent interest in the company. Quebec-based ProMetic said Tuesday …
Read more on CanadianBusiness.com

Leave a Reply